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It is generally accepted that androgenic hormones play an important role in
the pathogenesis of acne vulgaris. Various studies have indicated that there is an
increase in the androgen-estrogen ratio in patients with the disease (1), and
Hamilton (2) has shown that administration of testosterone to male castrates
will produce acne in many of them. It also is well known that testosterone will
produce acne (along with masculinizing effects) when given to normal females.
The source of androgen in the female is considered to be the adrenal cortex pri-
marily, and in males a significant proportion of androgen is derived from the
adrenal, although the testis is the more important source.
The development of knowledge concerning the suppressive effect of cortisone
on adrenal cortical function was, therefore, of interest because of its possible ap-
plication to an understanding of the problem of acne.
Cortisone in therapeutic doses is known to temporarily suppress the activity
of the adrenal cortex by inhibiting pituitary adrenocorticotropin (ACTH) output
in patients receiving the hormone (3). More recently it has been shown by Wil-
kins and co-workers (4) and by others that amounts of cortisone smaller than the
usual therapeutic doses will reduce the abnormally high output of 17-ketosteroids
in patients with congenital adrenal hyperplasia and will suppress or reverse the
clinical signs of virilism seen in these patients. The virilization and the abnormal
hormone excretion are considered due to excess production of androgenic hor-
mone by the adrenal cortex. Cortisone in amounts ranging from 25 to 50 or more
milligrams daily (in adults) will cause the 17-ketosteroid excretion to return to
levels found in normal individuals and apparently will not interfere with the
normal adrenal response to stress.
Because of the facts cited above, a brief clinical study into the effect of small
doses of cortisone in patients with acne was undertaken. No facilities were avail-
able for determinations of hormone blood levels or excretion.
DETAILS OF THE STUDY
Nine females, with ages ranging between 18 and 34 years, and eight males be-
tween 16 and 21 years of age with papular and comedone types of acne were given
cortisone. The average dose was 25 mg. daily, although four patients received 50
mg. daily for the first two days of their course; two others received 50 mg. daily
for their entire course of six and 14 days respectively. One of the latter patients
was especially heavy, weighing 225 pounds. Two of the 17 patients received part
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of their course by the intramuscular route, 50 mg. at intervals of two or three
days. The remaining patients took the hormone orally. Periods of administration
varied from six to 28 days, but the majority were of ten to 14 days' duration.
Four patients received more than one course of the hormone.
Evaluation of results was on the basis of clinical appraisal and on changes
noted by the patients. In many of the patients no other treatment was given
during the time of cortisone administration; some continued to use routine local
therapy with sulfur-rcsorcin lotion previously prescribed. In seven patients, in-
cluding two males, estrogen had been administered for varying periods of time
(prcmenstrually in the females) prior to cortisone; in three of these the hormone
was started immediately after discontinuance of the estrogen, and in four the
cortisone was given one to six weeks after the last dose of estrogen.
RESULTS
Seventeen patients (eight males and nine females) received cortisone. Five of
these, including one male, showed a discernible effect. These cases are presented
in detail.
Case 1—Seventeen year old male with moderate numbers of deep, cystic comedones and
a few inflammatory papules. Ethinyl estradiol* 0.05 mg. had been given daily for 24 days,
with slight breast tenderness noted on the 22nd day. One week after the end of this course,
cortisone was given, 50 mg. daily during the first two days, then 25 mg. daily for eight days.
At the end of this time there was a 50 per cent reduction in the number of cystic comedones
and a slight reduction in the number of inflammatory papules. No other changes were noted.
The patient returned three months later for observation. At this time he still had fewer
comedones than were present initially, but he had a mild increase in the number of in-
flammatory papules. Cortisone was again given on the same schedule. At the end of eight
days there was no appreciable change. There was no follow-up. No estrogen was admin-
istered prior to the second course of cortisone.
Case 2—Twenty-three year old single female with many deep, cystic comedones on face,
oily skin, and a moderate number of inflammatory papules. The response to local therapy,
tcrramycin orally, acne surgery, and premenstrual administration of ethinyl estradiol for
four months had been very poor. The estrogen was given in increasing doses, finally reach-
ing 0.1 mg. daily for six days immediately prior to cortisone. The latter was given for 14
days at the rate of 25 mg. daily. At the end of the course there was an estimated 80 per cent
reduction in the number of cystic comedones, and the patient thought the skin was less
oily. At the next menstrual period the usual flare did not occur, and the improvement was
maintained for four months. Eight months after cortisone the patient returned, having had
a gradual increase in comedones and papules for three and one-half months, but the skin
was not as bad as it had been originally. Cortisone was again given, 25 mg. daily for 28
days. The response this time was less marked. Comedones were moderately reduced, hut in-
flammatory papules were not affected. No estrogen was given prior to the second course.
Case 3—Twenty-eight year old single female who had had acne for 12 or 14 years. She
showed an oily skin, numerous small scars, and a moderate number of medium-sized in-
flammatory papules and occasional pustules. She also suffered from mild bronchiectasis.
She was treated with a sulfur-containing liquid locally, and by premenstrual estrogen for
six months. The hormone produced a definite reduction in oiliness and a moderate reduction
in the papules on a schedule of 0.04 mg. of cthinyl estradiol daily for 14 days before each
menstrual period. During the last two months on this schedule, she also was given terra-
*Estinyl, Schering Corporation, Bloomfield, N. J.
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mycin with marked improvement in the inflammatory papules. Prior to the menstrual period
at the seventh month, after having had no estrogen for two and one-half weeks (during
which time the oiliness had returned), she was given cortisone, 50 mg. daily for two days,
then 50 mg. every second day to a total of ten days just before the menstrual period. Terra-
mycin also was given for three or four days just prior to the menstrual period. The patient
noted the same reduction in oiliness of the skin while on cortisone that she had experienced
with the estrogen, and the change was noted prior to addition of the terramycin. Cortisone
was repeated in the following month, again for ten days prior to menstruation, with the
same effect. During this time the patient experienced an exacerbation of her chronic chest
infection, with a tight cough, for which she took potassium iodide for three days. This was
accompanied by a considerable exacerbation in the papular element of her acne for a few
days during the period of cortisone adrninistratiom
Case 4—Thirty-four year old single female who had experienced mild adolescent acne,
followed by occasional papules for several years. In the two months prior to her examination
she had noted a number of lesions on the chin and inferior to the anterior portions of the
mandihies. These lesions consisted of shallow, relatively small inflammatory papules and
scattered, deep, cystic type comedones. The skin was not excessively oily. Estrogen therapy
was contemplated, and later used, hut first she was given cortisone for ten days. The dose
was 50 mg. daily for two days, then 50 mg. every second day for four more doses. There was
a reduction of about 50 per cent in the number of deep comedones but no change in the in-
flammatory papules. Although her skin was not especially oily, the patient stated that while
on the cortisone (and also when on ethinyl estradiol later) she was able to use less face
powder than usual because the skin was less oily, smoother, and the powder remained in
place for a longer time. This change was noted after five days of therapy with either hor-
mone. No objective change in the texture of the skin was discernible, however. Subsequently
the patient took ethinyl estradiol premenstrually for several months with almost complete
clearing of the lesions.
Case 5—Eighteen year old girl with severe acne of four or five years duration. She had
received six x-ray treatment of 75 r each in 1950 and six in 1951 with temporary improve-
ment. Six months after the second series of treatments she had many comedones over the
entire face and scattered inflammatory papules. During 1952 she received considerable
treatment, including various local remedies, premenstrual estrogen therapy, terramycin,
vitamin A, and desiccated thyroid. There was temporary improvement from the estrogen
but the effect was not maintained upon further therapy during eight menstrual cycles. Six
weeks after the last estrogen administration, cortisone was given at the rate of 25 mg. daily
for ten days, during which time she failed to have the usual menstrual flare. At the end of the
course there was a moderate but definite reduction in the comedones and papules, but a
relapse to the previous condition occurred within three days. A second course of cortisone
was started two weeks prior to the next menstrual period, 25 mg. daily for the first week, and
25 mg. every second day during the second week. Initial improvement was again noted, but
before the dose was reduced there was a mild relapse, which increased on the lower dosage.
Two weeks later she was worse than before the cortisone was given. Subsequently diethyl-
stilbestrol was applied in a shake lotion and erythromycin was given orally without effect.
Vitamin A in aqueous solution* was started at a dose of 100,000 units daily. Two weeks later
the patient was again given cortisone, 25 mg. daily, plus ethinyl estradiol, 0.02 mg. daily for
two weeks. There was a mild improvement in the skin, so both hormones were again given,
but the dose of estrogen was increased to 0.04 mg. daily and the administration was started at
the end of the menstrual period and given for 18 days, presumably producing an anovulatory
cycle. At the end of this time there was a further slight improvement. The same schedule
was repeated and the patient returned six weeks after its completion. At this time the skin
was markedly improved, both as to comedones and papules, appearing better than at any
* Aquasol A., 50,000 unit capsules, U. S. Vitamin Corporation, 250 East 43rd Street,
New York City 17, New York.
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time in 18 months. The patient stated that the improvement began during the third course
of combined estrogen and cortisone, and the improvement was maintained during the
ensuing six weeks. She was still taking Vitamin A, which had previously been given 18
months earlier without effect.
The remaining 12 patients showed no significant effect. Eight of these received
no estrogen at any time prior to the cortisone; two had taken ethinyl estradiol for
14 days immediately preceding the cortisone; and two others had had estrogen
therapy terminated six weeks and 11 weeks before cortisone (the former was a
female on premenstrual estrogen for five months and the latter a male who re-
ceived a single course for 21 days). Several of these patients had moderate to
marked oiliness of the skin which was unaffected by the hormone. Two of the
females in the failure group received the cortisone by intramuscular injection at
the rate of 50 mg. every two or three days.
DISCUSSION
It is seen that four of the five improved cases had received estrogen, either
during, immediately before, or within six weeks of the cortisone administration,
whereas only two of the failure cases had had previous estrogen. In three of the
improved cases who received more than one course of cortisone, it appeared that
the courses given after estrogen administration were more effective than those
given at a more remote time after estrogen. The explanation for this apparent
potentiating effect of estrogen, if it is valid, is not known.
It is also interesting to note that the most severe patient (Case 5) in the im-
proved group, who had previously had little effect from all types of therapy, in-
cluding estrogen, was remarkably improved by cortisone combined with estrogen,
the latter being given on an ovulation suppressing schedule.
An additional factor of interest is the fact that in some of the patients the effect
on the oiliness of the skin which was noted after cortisone was identical to that
which was produced at a separate time by estrogen.
Since 70 per cent of the patients showed no discernible effect from cortisone,
doubt is cast on the validity of one or both of the original premises; namely, that
adrenal androgen influences acne, and that cortisone in small amounts reduces
adrenal androgen in patients with acne. Since the termination of the observa-
tions, a report has been published by Gardner (5) in which he noted a reduction
of slightly elevated 17-ketosteroid excretion in women with idiopathic hirsutism
when relatively small amounts of cortisone were administered. As part of his
control, cortisone was given to two normal women and there was no effect on
their 17-ketosteroid excretion. This would give weight to the belief that the
adrenal suppressive effect desired in the acne patients studied actually was not
produced.
Still to be explained, however, are the five patients (30 per cent of the total)
who noted a definite beneficial effect from the cortisone. It is felt that these
changes were not due to chance or to factors other than cortisone, since the effect
was sharp and was lost shortly after the cortisone was stopped in three of the
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cases. Other treatment factors were unaltered or had previously been shown to
produce no effect prior to the cortisone.
The mechanism of this effect of cortisone could be explained on the assumption
that in a small percentage of acne patients the adrenal production of androgen is
higher than normal and is reduced by cortisone. Other possibilities undoubtedly
exist, but exact explanations will await more complete studies. It is believed that
cortisone may be a useful tool in helping to clarify some of the endocrine problems
concerned in acne vulgaris.
SUMMARY
1) Seventeen pat.ients with acne vulgaris (eight males and nine females) were
given one or more courses of cortisone in doses averaging 25 mg. daily for periods
of ten to 28 days in an attempt to benefit the skin by the known adrenal suppres-
sive effect of the hormone.
2) The patients were evaluated on a purely clinical basis as follows. Four fe-
males and one male noted mild to moderate suppression of oiliness and reduction
in the number of comedones. This effect was temporary in two females and in the
male. Two other females noted a prolonged suppression of comedone and papule
formation after stopping cortisone, for three months in one and for more than
six weeks in the other.
3) Twelve patients noted no effect from the cortisone.
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